Bergen, 17 January 2006: NorDiag ASA (NORD) today received notification that the Stockholm regional council has decided to reimburse Genefec™, NorDiag’s DNA based test for detection of colorectal cancer, in the Stockholm region.

Genefec™ was launched in Sweden in December 2005 in collaboration with Capio Sankt Görans Hospital AB, a subsidiary of NorDiag’s cooperative partner Capio Diagnostics, to about 1000 of their clinical users in the Stockholm area. Capio which has been NorDiag’s partner in Norway since the launch of Genefec in 2002, has exclusive distribution rights to the product in the Scandinavian market.

- This is a mark of quality for the Genefec™ test, says the NorDiag CEO, Christian Horn. It is also good news for possible reimbursement in other areas of Sweden as the test is being introduced there.

The reimbursement entails that the local government in the Stockholm region will pay Capio a fixed fee of SEK 2.500 per Genefec™ test.

For further information, please contact:

Christian Horn, CEO, NorDiag ASA: +47 90163153

About Capio
Capio is one of the leading participants at the Health Market in Europe, hospital and diagnostic laboratory operations in Sweden, Norway, Denmark, Finland, Great Britain, France, Spain and Switzerland. Capio has an annual turn over of about NOK 12 billion and has about 14 000 employees.

About NorDiag ASA
NorDiag is a biotechnology company with a focus on the early detection of cancer. The company’s first product is GenefecTM, a genetic test for early detection of gastro intestinal cancer, including colorectal cancer. NorDiag is listed at the Oslo Stock Exchange with the ticker: NORD.